Role of cell cycle biomarkers in human papillomavirus related uterine lesions

Current Pharmaceutical Design

Volumn 19, Issue 8, 2013, Pages 1412-1424

  Conesa Zamora, Pablo ^a  

^a Santa Lucia University Hospital HGUSL   (Spain)

Author keywords

Cervical carcinoma; Cyclin D1; Human papillomavirus; Ki67; p16; p53; ProEx C; Squamous intraepithelial lesion

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN E; CYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; PROTEIN P16; PROTEIN P53; TRANSCRIPTION FACTOR E2F; VIRUS DNA;

ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CHLAMYDIASIS; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE REPLICATION; GENOTYPE; GONORRHEA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYSTERECTOMY; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; UTERINE CERVIX DISEASE; VACCINATION; VIRUS CAPSID; VIRUS GENOME; VIRUS LOAD; WART VIRUS;

EID: 84876743247     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804805450     Document Type: Article

References (115)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on day/month/year.
2. Boronow RC. Death of the Papanicolaou smear? A tale of three reasons. Am J Obstet Gynecol 1998; 179: 391-6.
3. DeMay RM. The Pap smear. In: DeMay RM. Eds. The art and science of cytopathology. Chicago: American Society of Clinical Pathologists Press 1996; pp. 61-205.
4. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-41.
5. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
6. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002; 2:59-65.
7. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11-22.
8. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-9.
9. Wells M, Östor AG, Crum CP, et al. Tumors of the uterine cervix: epithelial tumors. In: Tavassoli FA, Devilee P. Eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003; pp. 262-79.
10. Park J, Sun D, Genest DR, Trivijitsilp P, Suh I, Crum CP. Coexistence of low and high grade squamous intraepithelial lesions of the cervix: morphologic progression or multiple papillomaviruses? Gynecol Oncol 1998; 70: 386-91.
11. Baak JPA, Stoler MH, Bean SM, Anderson MC, Robboy SJ. Cervical precancer, including functional biomarkers and colposcopy. In: Robboy SL, Mutter GL, Prat J, Bently RC, Russell P, Anderson MC Eds. Pathology of the Female Reproductive Tract. New York: Churchill Livingstone 2009; pp.189-226.
12. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249-56.
13. Trinh XB, Bogers JJ, Van Marck EA, Tjalma WA. Treatment policy of neuroendocrine small cell cancer of the cervix. Eur J Gynaecol Oncol 2004; 25: 40-44.
14. Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
15. Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999; 59: 6132-6.
16. Duggan MA. Cytologic and histologic diagnosis and significance of controversial squamous lesions of the uterine cervix. Mod Pathol 2000; 13: 252-60.
17. Crum CP, Egawa K, Fu YS, et al. Atypical immature metaplasia (AIM). A subset of human papilloma virus infection of the cervix. Cancer 1983; 51: 2214-9.
18. Duggan MA, Akbari M, Magliocco AM. Atypical immature cervical metaplasia: immunoprofiling and longitudinal outcome. Hum Pathol 2006; 37: 1473-81.
19. Iaconis L, Hyjek E, Ellenson LH, et al. p16 and Ki-67 immunostaining in atypical immature squamous metaplasia of the uterine cervix: correlation with human papillomavirus detection. Arch Pathol Lab Med 2007; 131: 1343-1349.
20. Geng L, Connolly DC, Isacson C, et al. Atypical immature metaplasia (AIM) of the cervix: is it related to high-grade squamous intraepithelial lesion (HSIL)? Hum Pathol 1999; 30: 345-351.
21. Conesa-Zamora P, Doménech-Peris A, Orantes-Casado FJ, et al. Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol 2009; 132: 378-90.
22. Mosher RE, Lee KR, Trivijitsilp P, Crum CP. Cytologic correlates of papillary immature metaplasia (immature condyloma) of the cervix. Diagn Cytopathol 1998; 18: 416-21.
23. Ge Y, Mody DR, Smith D, Anton R. p16(INK4a) and ProEx C immunostains facilitate differential diagnosis of hyperchromatic crowded groups in liquid-based Papanicolaou tests with menstrual contamination. Acta Cytol 2012; 56: 55-61.
24. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology. A systematic review and meta-analysis. Obstet Gynecol 2008; 111: 167-77.
25. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007; 335: 28.
26. Cox JT, Schiffman M, Solomon D; ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 1406-12.
27. Costa S, De Simone P, Venturoli S, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 2003; 90: 358-65.
28. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831-6.
29. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 1749-57.
30. Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 2002; 102: 519-25.
31. Schiffman M, Khan MJ, Solomon D, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 147-50.
32. Muñoz N, Bosch FX, de Sanjosé S, et al; for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
33. Conesa-Zamora P, Ortiz-Reina S, Moya-Biosca J, et al. Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain. BMC Infect Dis 2009; 9: 124.
34. De Marchi Triglia R, Metze K, Zeferino LC, Lucci De Angelo Andrade LA. HPV in situ hybridization signal patterns as a marker for cervical intraepithelial neoplasia progression. Gynecol Oncol 2009; 112: 114-8.
35. Samama B, Schaeffer C, Boehm N. P16 expression in relation to human papillomavirus in liquid-based cervical smears. Gynecol Oncol 2008; 109: 285-90.
36. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570-7.
37. Thrall MJ, Russell DK, Facik MS, et al. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. Am J Clin Pathol 2010; 133: 894-8.
38. Bahnassy AA, Zekri AR, Saleh M, et al. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol 2007; 7: 4.
39. Tsuda H, Hashiguchi Y, Nishimura S, et al. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003; 91: 476-485.
40. Zeng WJ, Li Y, Fei HL, et al. The value of p16ink4a expression by fluorescence in situ hybridization in triage for high risk HPV positive in cervical cancer screening. Gynecol Oncol 2011; 120: 84-8.
41. Zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994; 186: 131-156.
42. Murphy N, Ring M, Heffron CC, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005;58:525-34.
43. Nam EJ, Kim JW, Kim SW, et al. The expressions of the Rb pathway in cervical intraepithelial neoplasia: predictive and prognostic significance. Gynecol Oncol 2007; 104: 207-211.
44. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8.
45. Branca M, Ciotti M, Giorgi C, et al. Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. Int J Gynecol Pathol 2008; 27: 265-73.
46. Nieh S, Chen SF, Chu TY, et al. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol 2005; 97: 35-40.
47. Lambert AP, Anschau F, Schmitt VM. p16INK4A expression in cervical premalignant and malignant lesions. Exp Mol Pathol 2006; 80: 192-6.
48. Milde-Langosch K, Riethdorf S, Kraus-Pöppinghaus A, Riethdorf L, Löning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPVnegative cervical adenocarcinomas. Virchows Arch 2001; 439: 55-61.
49. Wang JL, Zheng BY, Li XD, Angström T, Lindström MS, Wallin KL. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004; 10: 2407-14.
50. Huang LW, Lee CC. P16INK4A overexpression predicts lymph node metastasis in cervical carcinomas. J Clin Pathol 2012; 65: 117-21.
51. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-42.
52. Reuschenbach M, Clad A, von Knebel Doeberitz C, et al. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol 2010; 119: 98-105.
53. Regauer S, Reich O. CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). Histopathology 2007; 50: 629-35.
54. Reuschenbach M, Seiz M, von Knebel Doeberitz C, et al. Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. Int J Cancer 2012; 130: 388-94.
55. Liang CW, Lin MC, Hsiao CH, Lin YT, Kuo KT. Papillary squamous intraepithelial lesions of the uterine cervix: human papillomavirus-dependent changes in cell cycle expression and cytologic features. Hum Pathol 2010; 41: 326-35.
56. Zhao P, Mao X, Talbot IC. Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol 2006; 12: 6391-6.
57. Emig R, Magener A, Ehemann V, et al. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 1998; 78: 1661-8.
58. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
59. Zhao CY, Szekely L, Bao W, Selivanova G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 2010; 70: 3372-81.
60. Silva-Filho AL, Traiman P, Triginelli SA, et al. Expression of p53, Ki-67, and CD31 in the vaginal margins of radical hysterectomy in patients with stage IB carcinoma of the cervix. Gynecol Oncol 2004; 95: 646-654.
61. Grace VM, Shalini JV, Lekha TT, Devaraj SN, Devaraj H. Cooverexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2003; 91: 51-8.
62. Ngan HY, Liu SS, Yu H, Liu KL, Cheung AN. Proto-oncogenes and p53 protein expression in normal cervical stratified squamous epithelium and cervical intra-epithelial neoplasia. Eur J Cancer 1999; 35: 1546-50.
63. Hiller T, Poppelreuther S, Stubenrauch F, et al. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 2006; 15: 1262-7.
64. Jain D, Srinivasan R, Patel FD, Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003 Jan; 88: 22-8.
65. Huang LW, Chou YY, Chao SL, Chen TJ, Lee TT. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol 2001; 83: 348-54.
66. Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenecker G, Reinthaller A. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol Oncol 1995; 57: 212-4.
67. Hunt CR, Hale RJ, Buckley CH, Hunt J. p53 expression in carcinoma of the cervix. J Clin Pathol 1996; 49: 971-4.
68. Ebara T, Mitsuhashi N, Saito Y, et al. Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. Gynecol Oncol 1996; 63: 216-8.
69. Giarnieri E, Mancini R, Pisani T, et al. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2000; 6: 3600-6.
70. Kim JW, Lee CG, Han SM, et al. Loss of heterozygosity of the retinoblastoma and p53 genes in primary cervical carcinomas with human papillomavirus infection. Gynecol Oncol 1997; 67: 215-21.
71. Kurvinen K, Syrjänen K, Syrjänen S. p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions. J Clin Oncol 1996; 14: 2120-30.
72. Giannoudis A, Herrington CS. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 2000; 89: 1300-7.
73. Zehbe I, Richard C, DeCarlo CA, et al. Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis. Virology 2009; 383: 69-77.
74. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-34.
75. Ueda M, Toji E, Nunobiki O, et al. Germline polymorphisms of glutathione-S-transferase GSTM1, GSTT1 and p53 codon 72 in cervical carcinogenesis. Hum Cell 2010; 23: 119-25.
76. Hu X, Zhang Z, Ma D, et al. TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 755-61.
77. Sarian LO, Derchain SF, Yoshida A, Vassallo J, Pignataro F, De Angelo Andrade LA. Expression of cyclooxygenase-2 (COX-2) and Ki67 as related to disease severity and HPV detection in squamous lesions of the cervix. Gynecol Oncol 2006; 102: 537-41.
78. Qiao X, Bhuiya TA, Spitzer M. Differentiating highgrade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis. J Low Genit Tract Dis 2005; 9: 100-107.
79. Verheijen R, Kuijpers HJ, van Driel R, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 1989; 92: 531-40.
80. Nichols GE, Williams ME, Gaffey MJ, et al. Cyclin D1 gene expression in human cervical neoplasia. Mod Pathol 1996; 9: 418-425.
81. Cheung TH, Yu MM, Lo KW, et al. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett 2001; 166: 199-206.
82. Bae DS, Cho SB, Kim YJ, et al. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 2001; 81: 341-7.
83. Vijayalakshmi N, Selvaluxmi G, Majhi U, et al. Alterations found in pl6/Rb/cyclin D1 pathway in the dysplastic and malignant cervical epithelium. Oncol Res 2007; 16: 527-533.
84. Conesa-Zamora P, Trujillo-Santos J, Orantes-Casado FJ, Ortiz-Reina S, Pérez-Guillermo M. Analysis of performance characteristics of five cell cycle-related immunohistochemical markers and human papillomavirus genotyping in the diagnosis of cervical squamous cell carcinoma precursor lesions. Anal Quant Cytol Histol 2012; 34: 49-55.
85. Carreras R, Alameda F, Mancebo G, et al. A study of Ki-67, cerbB2 and cyclin D-1 expression in CIN-I, CIN-III and squamous cell carcinoma of the cervix. Histol Histopathol 2007; 22: 587-592.
86. Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 812-821.
87. Santopietro R, Shabalova I, Petrovichev N, et al. Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21CIP1/WAF1, cyclin A in predicting cervical intraepithelial neoplasia, high-risk human papillomavirus infections and their outcome in women screened in three new independent states of the former Soviet Union. Cancer Epidemiol Biomarkers Prev 2006; 15: 1250-6.
88. Southern SA, Herrington CS. Differential cell cycle regulation by low-and high-risk human papillomaviruses in low-grade squamous intraepithelial lesions of the cervix. Cancer Res 1998; 58: 2941-5.
89. Cheung TH, Lo KW, Yu MM, et al. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett 2001; 172: 93-8.
90. Van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R. Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol 2004; 92: 40-6.
91. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011; 121: 505-9.
92. Shidham VB, Mehrotra R, Varsegi G, D'Amore KL, Hunt B, Narayan R. p16 immunocytochemistry on cell blocks as an adjunct to cervical cytology: Potential reflex testing on specially prepared cell blocks from residual liquid-based cytology specimens. Cytojournal 2011; 8: 1.
93. Gertych A, Joseph AO, Walts AE, Bose S. Automated Detection of Dual p16/Ki67 Nuclear Immunoreactivity in Liquid-Based Pap Tests for Improved Cervical Cancer Risk Stratification. Ann Biomed Eng. 2012 Jan 4. [in press]
94. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 2003; 63: 1927-35.
95. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005; 331: 269-91.
96. Romanowski P, Madine MA. Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6p and ORC. Trends Cell Biol 1997; 7: 9-10.
97. Conesa-Zamora P, Doménech-Peris A, Ortiz-Reina S, et al. Immunohistochemical evaluation of ProEx C in human papillomavirusinduced lesions of the cervix. J Clin Pathol 2009; 62: 159-62.
98. Shi J, Liu H, Wilkerson M, et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol 2007; 38: 1335-44.
99. Badr RE, Walts AE, Chung F, et al. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008; 32: 899-906.
100. Pinto AP, Schlecht NF, Woo TY, et al. Biomarker (ProEx C, p16(INK4A), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol 2008; 21: 1067-74.
101. Beccati MD, Buriani C, Pedriali M, Rossi S, Nenci I. Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquidbased cervical squamous cell cytology. Cancer 2008; 114: 196-203.
102. Shroyer KR, Homer P, Heinz D, Singh M. Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer 2006; 108: 324-30.
103. Kelly D, Kincaid E, Fansler Z, Rosenthal DL, Clark DP. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay (ProEx C). Cancer 2006; 108: 494-500.
104. Siddiqui MT, Cohen C, Nassar A. Detecting high-grade cervical disease on ASC-H cytology: role of BD ProEx C and Digene Hybrid Capture II HPV DNA testing. Am J Clin Pathol 2008; 130: 765-70.
105. Siddiqui MT, Hornaman K, Cohen C, Nassar A. ProEx C immunocytochemistry and high-risk human papillomavirus DNA testing in papanicolaou tests with atypical squamous cell (ASC-US) cytology: correlation study with histologic biopsy. Arch Pathol Lab Med 2008; 132: 1648-52.
106. Depuydt CE, Makar AP, Ruymbeke MJ, Benoy IH, Vereecken AJ, Bogers JJ. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiol Biomarkers Prev 2011; 20: 628-37.
107. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999; 5: 2121-32.
108. Sánchez-Hernández M, Conesa-Zamora P, García-Solano J, Corbalán-Vélez R, Martínez-Barba E, Pérez-Guillermo M. Expression profiles of ProEx C and Ki67 in squamous cell carcinoma in situ of the skin and their relationship with human papillomavirus genotypes. J Cutan Pathol 2010; 37: 730-6.
109. Sanati S, Huettner P, Ylagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol 2010; 29: 79-87.
110. Aximu D, Azad A, Ni R, Colgan T, Nanji S. A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol 2009; 28: 114-9.
111. Halloush RA, Akpolat I, Jim Zhai Q, Schwartz MR, Mody DR. Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquidbased cervicovaginal material: a pilot study. Cancer 2008; 114: 474-80.
112. Ozaki S, Zen Y, Inoue M. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol 2011; 42: 1007-12.
113. Walts AE, Bose S. p16, Ki-67, and BD ProExC immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol 2009; 40: 957-64.
114. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-10.
115. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7: 1359-73